Claudio Dansky Ullmann, MD

Doug Doerfler
President and Chief Executive Officer

Mr. Doerfler has 35+ years of vast experience in biotechnology product and company development, commercialisation and international financing. He was a founder of MaxCyte in July 1998. Previously, he was President, CEO and a Director of Immunicon Corporation. He also held various executive positions with Life Technologies, Inc. (now Thermo Fisher).

Mr. Doerfler is an active Life Sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the executive committee of the Biotechnology Innovation Organization. He received his BS in finance from the University of Baltimore School of Business, and holds an Industrial Relations certificate.

Claudio Dansky Ullmann, MD

Ron Holtz
Chief Financial Officer

Mr. Holtz joined MaxCyte in 2005. Previously, he had served as the CFO of both public and private companies. He also had previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.

Claudio Dansky Ullmann, MD

Thomas M. Ross
Executive Vice President, Global Sales and Marketing

Mr. Ross has extensive experience in commercial operations and 30+ years of successful life sciences and clinical diagnostics sales and marketing leadership. Most recently, he was SVP of Commercial Operations at OpGen. He also served as Chief Commercial Officer at Predictive BioScience and VP of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. He previously held senior leadership roles in Manufacturing Operations at Life Technologies, Inc. and Cambrex. Mr. Ross holds a BA in business administration from The Citadel.

Claudio Dansky Ullmann, MD

Maher Masoud
Executive Vice President and General Counsel

Mr. Masoud has 20+ years of experience in the biopharmaceutical industry, including 15 years as an attorney and general counsel. He has served as: Assistant General Counsel and Corporate Secretary for Wellstat Management Company; co-founding partner of Rossi/ Masoud LLC; and Corporate Attorney at Human Genome Sciences, Inc. A member of the Maryland State Bar, Mr. Masoud holds a JD from Michigan State University College of Law, and a BS in cell and molecular biology genetics from the University of Maryland.

Claudio Dansky Ullmann, MD

Cenk Sumen
Chief Scientific Officer

Dr. Sumen boasts over a decade of scientific, technological and business development expertise, with extensive time in leadership roles for Stemson Therapeutics, where he was the Chief Technology Officer and led all aspects of technology, scale-up, process development and automation, as well as Thermo Fisher Scientific and Hitachi Chemical Advanced Therapeutics Solutions. He holds a Ph.D. in Microbiology and Immunology from Stanford University, post-doctoral training at Harvard and a fellowship at the Cancer Research Institute, working at Memorial Sloan Kettering Cancer Center under Nobel Laureate Dr. Jim Allison. He is also currently an Adjunct Professor in the Department of Chemical and Biomolecular Engineering at the NYU Tandon School of Engineering.

Claudio Dansky Ullmann, MD

Steve Nardi
Executive Vice President, Manufacturing and Engineering Operations

Before joining MaxCyte, Mr. Nardi served as Vice President of Worldwide Manufacturing at Iradimed Corporation where he introduced lean manufacturing principles, and improved transparency, cost control and accountability. Prior to his work at Iradimed, Mr. Nardi was the Senior Manager of Manufacturing and Engineering at Haemonetics Corporation. He received both a BS in science, engineering and technology and an MS in technology commercialization at Northeastern University.

Claudio Dansky Ullmann, MD

James Brady, PhD
Senior Vice President, Technical Applications and Customer Support

Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments. Previously, he worked at MetaMorphix, Inc., and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a BS degree in biology from the College of William and Mary, a PhD in genetics from Indiana University and an MBA from Johns Hopkins University.

Claudio Dansky Ullmann, MD

Sarah Haecker Meeks, PhD
Senior Vice President, Business Development

Before joining MaxCyte, Dr. Meeks served as Vice President of Business Development at Synpromics (now part of AskBio) where she established a leading market position for the company, including partnerships with leading gene therapy companies, and led broad technology education and adoption initiatives. Prior to her work at Synpromics, she was the Chief Scientific Officer at Adjuvant Partners. She received a PhD in biochemistry, molecular biology and biophysics, with a minor in bioethics, from the University of Minnesota and completed postdoctoral work in the University of Pennsylvania Gene Therapy Program and Center for Technology Transfer with continued education in the Wharton MBA Program.

Claudio Dansky Ullmann, MD

James Lovgren
Senior Vice President, Global Marketing

James is an accomplished life science executive with a distinguished track record of commercializing disruptive technologies and managing industry-leading global product portfolios. His background includes working at startups, growth-stage, and Fortune 150 biotechnology companies. Most recently, he served as the Vice President of Cell Therapy at Berkeley Lights, and as the General Manager of Cell and Gene Therapy at Thermo Fisher Scientific. Jim holds a BS in Biology from the University of North Florida and an MBA from North Carolina State University.

Claudio Dansky Ullmann, MD

Gene Zhu, PhD
Vice President of Regulatory

Dr. Zhu brings over 17 years of regulatory experience to his role at MaxCyte. During his career, he has been instrumental in supporting companies receive regulatory approvals of several biologics, including approvals for the treatment of post-transplant lymphoproliferative disease (PTLD), breast cancer, lung cancer, rheumatoid arthritis, eczema, asthma, gout, cytokine release syndrome, etc.
Prior to joining MaxCyte, Dr. Zhu served as Head of Regulatory Affairs CMC at Atara Biotherapeutics. Previously, he held the positions of: Head of Regulatory Affairs CMC at Daiichi Sankyo, Inc., Senior Director of Regulatory Affairs CMC at Regeneron Pharmaceuticals, Senior Director of Regulatory Affairs CMC at Savient Pharmaceuticals, Inc., and Associate Director at Chugai Pharma USA. Dr. Zhu earned his PhD in genetic engineering from Ghent University and his BS from Fudan University.

Claudio Dansky Ullmann, MD

Jill Mayer
Vice President, Talent and Teamwork

Ms. Mayer joined MaxCyte in 2018, bringing over 20 years of broad, cross-industry human resources leadership experience. With a passion for people, Ms. Mayer has developed comprehensive human resources programs and partnered with leaders in both public and private companies to build strong, engaged organizations and teams. Prior to MaxCyte, Ms. Mayer served in human resources leadership roles at Fluke Networks, Entremed, The American Chemical Society, and Peak Technologies. Ms. Mayer holds a Masters degree in Psychology from the University of Delaware and a BA in Psychology from the University of Pennsylvania.

Learn about cutting-edge applications, new resources, and upcoming events.
Subscribe to our e-Newsletter

Sign Up